-transparent.png){kind=logo}
To evaluate the prognostic value of prostate-specific antigen (PA) for detection of tumor growth after definitive therapy, 602 sera from 70 patients with stages B2 to D1 prostate cancer (26 of whom recurred) were analyzed in a blind study. Using Cox's proportional-hazards model, a highly significant association was found between serially measured PA and disease-free survival time (p = 0.0002). A positive predictive value of 100% was found for some markedly elevated PA levels and confirmed recurrence of disease. In fact, this study suggested that once a PA level of 88 ng/ml was reached, there was an average time of less than 2 months before a recurrence was clinically confirmed. Tumor growth in patients who recurred was indicated by a PA elevation before recurrence in 92% (24 of 26) as opposed to 20% (9 of 44) in disease-free patients. Additionally, in these 24 of 26 patients, levels of PA were elevated 12 months (mean lead time) before a confirmed disease recurrence. In patients who were still disease free, serial PA appeared to increase concurrently with putative tumor growth as shown by the initial surgical stage. Generally, the greater the PA level the more advanced was the stage of disease (B2 to D1). These data suggest that PA may be a useful adjuvant marker for monitoring tumor growth in patients with regionally confined prostate cancer.
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
November 1985,
Cancer research,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
January 2005,
TheScientificWorldJournal,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
September 2021,
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
July 1996,
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
January 2006,
International urology and nephrology,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
January 2008,
Japanese journal of clinical oncology,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
January 1994,
Mayo Clinic proceedings,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
September 1993,
International journal of radiation oncology, biology, physics,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
January 1990,
Urological research,
C S Killian, and
N Yang, and
L J Emrich, and
F P Vargas, and
M Kuriyama, and
M C Wang, and
N H Slack, and
L D Papsidero, and
G P Murphy, and
T M Chu
March 2011,
Der Urologe. Ausg. A,
